New WHO Initiative "Good Pharmacopoeial Practices"
Recommendation
20/21 October 2026
Performance Evaluation and Monitoring for compliant Analytical Procedures and Processes
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
The WHO started the new initiative "Good Pharmacopoeia Practices" with the goal to harmonise the procedures and the regulations for pharmaceutical standards. It is supposed to support authorities in ensuring the quality of pharmaceutical raw materials and finished products.
The background for the initiative is that the retrospective harmonisation of pharmacopoeia requirements has proven to be difficult. A prospective harmonisation seems to be easier to accomplish. In the end the initiative is supposed to result in the harmonisation of pharmacopoeia standards.
Representatives of all pharmacopoeias are involved in this activity.
The WHO working document comprises an agenda with the planned activities. For instance, in June 2013 it was planned to discuss the feedback that was submitted with regard to the concept paper.
For more detailed information please see the concept paper "Good Pharmacopoeia Practices".
Related GMP News
07.10.2026Analytical Quality Group Developments May through August 2026
07.10.2026Two New FDA Warning Letters Put OOS Investigations in Focus
07.10.2026Pharmeuropa: Revision Proposed for Chapter 2.5.32 on Coulometric Karl Fischer Water Determination
30.09.2026The Relationship between the BP and the Ph. Eur.
30.09.2026New Japanese Pharmacopoeia Drafts (September 2026) Open for Public Comment
30.09.2026EMA publishes final ICH M13B Guideline and Q&A on Bioequivalence